Rare-disease advocates challenge FDA on gene-therapy approvals
TL;DR Summary
Advocates for rare diseases express concern after the FDA rejected Regenxbio’s MPS type 2 gene therapy and signals a more cautious, data-heavy approval path that could delay access to promising treatments highlighted by newborn screening.
- Rare disease advocates fume over FDA’s mixed signals statnews.com
- 'Like talking to a brick wall': Senate hearing takes aim at FDA's rare disease review process Fierce Biotech
- How Trump’s FDA is breaking his promise to America’s patients New York Post
- Senate Committee Holds Hearings to Examine FDA Bureaucracy: ‘From Regulator to Roadblock’ NTD News
- Biohaven says FDA roadblocks leave rare disease patients in limbo PharmaVoice
Reading Insights
Total Reads
1
Unique Readers
3
Time Saved
2 min
vs 3 min read
Condensed
93%
479 → 35 words
Want the full story? Read the original article
Read on statnews.com